Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e14665

Conclusions: The combination of Nous-209 and pembrolizumab is safe, well tolerated and shows encouraging clinical efficacy in patients with treatment-naive dMMR/MSI-H mCRC eligible for anti-PD-1 therapy.

The study is ongoing and expanding to Phase II randomisation with a new accelerated Nous-209 vaccination schedule.